-
Prediction of stillbirth from placental growth factor at 11-13 weeks.
Akolekar R, Machuca M, Mendes M, Paschos V, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;48:618-23. pdf -
Contingent screening for preterm pre-eclampsia.
Wright D, Gallo DM, Gil Pugliese S, Casanova C, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:554-9. pdf -
Prediction of large-for-gestational-age neonates: screening by maternal factors and biomarkers in the three trimesters of pregnancy.
Frick AP, Syngelaki A, Zheng M, Poon LC, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:332-9. pdf -
Biophysical and biochemical markers at 35-37 weeks' gestation in the prediction of adverse perinatal outcome.
Valiño N, Giunta G, Gallo DM, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:203-9. pdf -
Biophysical and biochemical markers at 30-34 weeks' gestation in the prediction of adverse perinatal outcome.
Valino N, Giunta G, Gallo DM, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:194-202. pdf -
First trimester prediction of HELLP syndrome.
Oliveira N, Poon LC, Nicolaides KH, Baschat AA.
Prenat Diagn 2016;36:29-33. pdf -
Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks gestation.
O'Gorman N, Wright D, Syngelaki A, Akolekar R, Wright A, Poon LC, Nicolaides KH.
Am J Obstet Gynecol 2016;214:103.e1-103.e12 . pdf -
Contingent Screening for Small by Weight for Gestational Age Neonates.
Frick AP, Nicolaides KH, Poon LC.
Pediatr Endocrinol Rev 2016;13:568-73. -
First-trimester biochemical markers of placentation in screening for gestational diabetes mellitus.
Syngelaki A, Kotecha R, Pastides A, Wright A, Nicolaides KH.
Metabolism 2015;64:1485-9. pdf -
First-trimester maternal factors and biomarker screening for preeclampsia.
Poon LC, Nicolaides KH.
Prenat Diagn 2014;34:618-27. pdf -
First-trimester screening for trisomies 21, 18 and 13 by ultrasound and biochemical testing.
Wright D, Syngelaki A, Bradbury I, Akolekar R, Nicolaides KH.
Fetal Diagn Ther 2014;35:118-26. pdf -
First-trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell-free DNA testing.
Nicolaides KH, Wright D, Poon LC, Syngelaki A, Gil MM.
Ultrasound Obstet Gynecol 2013;42:41-50. pdf -
First-trimester contingent screening for trisomies 21, 18 and 13 by biomarkers and maternal blood cell-free DNA testing.
Nicolaides KH, Syngelaki A, Poon LC, Gil M, Wright D.
Fetal Diagn Ther 2014;35:185-92. pdf -
Combined screening for preeclampsia and small for gestational age at 11-13 weeks.
Poon LC, Syngelaki A, Akolekar R, Lai J, Nicolaides KH.
Fetal Diagn Ther 2013;33:16-27. -
Maternal Serum Placental Growth Factor, Pregnancy-Associated Plasma Protein-A and Free β-Human Chorionic Gonadotrophin at 30-33 Weeks in the Prediction of Pre-Eclampsia.
Lai J, Pinas A, Poon LC, Agathokleous M, Nicolaides KH.
Fetal Diagn Ther 2013;33:164-72. -
Competing risks model in early screening for preeclampsia by biophysical and biochemical markers.
Akolekar R, Syngelaki A, Poon L, Wright D, Nicolaides KH.
Fetal Diagn Ther 2013;33:8-15. -
Body Mass Index at 11-13 Weeks' Gestation and Pregnancy Complications.
Syngelaki A, Bredaki FE, Vaikousi E, Maiz N, Nicolaides KH.
Fetal Diagn Ther 2011;30:250-65. -
Reference range of birth weight with gestation and first-trimester prediction of small-for-gestation neonates.
Poon LC, Karagiannis G, Staboulidou I, Shafiei A, Nicolaides KH.
Prenat Diagn 2011;31:58-65. -
Screening for fetal aneuploidies at 11 to 13 weeks.
Nicolaides KH.
Prenat Diagn 2011;31:7-15. -
Prediction of small-for-gestation neonates from biophysical and biochemical markers at 11-13 weeks.
Karagiannis G, Akolekar R, Sarquis R, Wright D, Nicolaides KH.
Fetal Diagn Ther 2011;29:148-54.